Tag:

Smith & Nephew

Latest Headlines

Latest Headlines

Smith & Nephew to shutter 20+-year-old site in U.K.

Orthopedics company Smith & Nephew plans to close its York, U.K., facility by the end of 2016, resulting in the relocation of 80 jobs.

Smith & Nephew removes some hip implants from market, cautions on indicated use

Orthopedics specialist Smith & Nephew is removing particular hip implant sizes and related components from the market after data from the U.K.'s National Institute for Health and Care Excellence found that smaller sizes of the Birmingham Hip Resurfacing System had revision rates that exceed its benchmarked expectations. It's also advising against any use of the system in women. But despite the data, it's not advising that patients with the now-contraindicated implant have proactive revisions.

S&N backs OrthoSpace in $8M for pivotal U.S. trial of rotator cuff repair tech

Outside of surgery, physicians can do very little to treat severe rotator cuff tears. Israeli company OrthoSpace is aiming to offer a new treatment option. It's raised an $8 million venture round led by Healthpoint Capital that will finance a pivotal, U.S. trial for the company's biodegradable balloon system InSpace.

Smith & Nephew boosts rep-less sales pilot by acquiring software assets that help automate training

With the acquisition of two medical software programs from Andover, MA's S2 Interactive, Smith & Nephew is throwing more chips on the table when it comes to its disruptive, rep-less sales pilot program.

FDA issues warning letter to Smith & Nephew regarding questionable operations at plant in Andover, MA

The FDA slapped Smith & Nephew with a warning letter for quality-control violations at its Andover, MA, facility related to problems with some of the company's mechanical morcellators for removal of intrauterine tissue. The company has placed a hold on shipments of its Truclear Ultra Reciprocating Morcellator 4.0 while it further investigates customer complaints.

S&N falls on Stryker buyback plan, buys into Latin American distributor

Smith & Nephew was down 8% on the March 3 news that Stryker now has a massive $2.6 billion authorization available for share repurchases. That's a significant shift in strategy for Stryker, which has been highly acquisitive in the last few years and has long been rumored as a potential buyer for Smith & Nephew.

S&N touts acquisition track record, says appetite remains 'undiminished'

Smith & Nephew is working toward having two-thirds of its revenue coming from higher growth areas. Acquisitions are core to that goal--in fact, during the fourth quarter any organic growth was wiped out by the impact from currency exchange and the only revenue growth came from its surgical devices acquisitions, which grew by 12%.

Stryker digests a string of acquisitions--and it's a top priority to add more

An aggressive acquisition strategy in order to broaden its product usage in trauma units and hospitals continues to be the focus for Stryker.

At JP Morgan, Stryker CEO embraces sales reps, dismisses Smith & Nephew plan to eliminate them

Stryker CEO Kevin Lobo expounded on the importance of specialized sales forces during his presentation at the JP Morgan Healthcare Conference in San Francisco and took a jab at Smith & Nephew's contrasting rep-less pilot program, which aims to cut implant prices in half through the use of automation.

Rumors that Stryker will buy Smith & Nephew pick up steam

Bloomberg reports that Stryker is planning to offer a premium for the U.K.'s S&N of about 30%. Currently, the target has a valuation of about $16.3 billion. The sources say a tax inversion is not planned. However, one of the unnamed sources also says Stryker's management could change its mind.